Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human
endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical
role in multiple sclerosis (MS).
This study evaluates the effect on MRI lesions parameters, the safety and pharmacokinetics of
GNbAC1 in patients with relapsing remitting multiple sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
GeNeuro SA
Collaborators:
Institut de Recherches Internationales Servier Les Laboratoires Servier (LLS) Worldwide Clinical Trials